news roundup
Over recent years global drug companies large or small have recognized that one root cause of the high failure rate in their clinical development lies in the selection of right therapeutic targets. More compounds fail in clinical trials because of the lack of necessary efficacy than any other reasons.
One way to reduce off-label prescribing of treatments for cancer and other conditions is for manufacturers to test additional indications and file supplemental applications to add those uses to approved labeling. The problem is that the testing and approval process for supplements takes a lot of time and money.
In 2014, the European Medicines Agency (EMA) recommended the highest number of orphan designated medicines for marketing authorization in a year. Out of the 82 medicines for human use recommended in 2014, 17 are intended for the treatment of a rare disease.
|
|
|
Subscribe
|
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Eligendi ipsam eos amet! Rem nisi id sit similique, mollitia facere voluptatum beatae repellat!
Subscription offers »
|
|
|
|
Articles
Development of a compound in the oncology therapeutic area is constantly evolving, and costs are rising dramatically, making every step count. Three essential assets should be acquired before an oncology trial is launched.
Advertisment
|
|
|
BLOGS
Nominations are now open for the Partnerships in Clinical Trials conference. Award categories include: Clinical Innovator of the Year Award, Partnership Hall of Famer Award, and Woman of the Year Award.
Progression-Free Survival (PFS) has become a standard improvement measurement in oncology clinical trials. Nevertheless, some argue that PFS is not a sufficient measurement for delivering improvements in patient quality of life (QOL).
Advertisment
|
|
|
|
|
|
Read the digital edition of Applied Clinical Trials
Click here to sign up or renew your subscription
|
|
|
|
|
